PALATIN TECHNOLOGIES INC (PTN)
US6960775020 - Common Stock
PTN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. Both the profitability and financial health of PTN have multiple concerns. PTN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PTN had negative earnings in the past year.
In the past year PTN has reported a negative cash flow from operations.
PTN had negative earnings in each of the past 5 years.
PTN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PTN has a worse Return On Assets (-283.18%) than 94.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -283.18% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTN has a Gross Margin of 97.83%. This is amongst the best in the industry. PTN outperforms 97.50% of its industry peers.
PTN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for PTN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
2. Health
2.1 Basic Checks
PTN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTN has been increased compared to 1 year ago.
The number of shares outstanding for PTN has been increased compared to 5 years ago.
The debt/assets ratio for PTN has been reduced compared to a year ago.
2.2 Solvency
PTN has an Altman-Z score of -65.15. This is a bad value and indicates that PTN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PTN (-65.15) is worse than 95.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -65.15 |
ROIC/WACCN/A
WACC10.83%
2.3 Liquidity
A Current Ratio of 1.01 indicates that PTN should not have too much problems paying its short term obligations.
PTN has a Current ratio of 1.01. This is amonst the worse of the industry: PTN underperforms 88.95% of its industry peers.
A Quick Ratio of 1.01 indicates that PTN should not have too much problems paying its short term obligations.
PTN has a worse Quick ratio (1.01) than 86.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 18.18% over the past year.
The Revenue has decreased by -7.53% in the past year.
Measured over the past years, PTN shows a very negative growth in Revenue. The Revenue has been decreasing by -40.52% on average per year.
EPS 1Y (TTM)18.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.05%
Revenue 1Y (TTM)-7.53%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%-80.14%
3.2 Future
Based on estimates for the next years, PTN will show a very strong growth in Earnings Per Share. The EPS will grow by 30.24% on average per year.
Based on estimates for the next years, PTN will show a very strong growth in Revenue. The Revenue will grow by 162.67% on average per year.
EPS Next Y0.95%
EPS Next 2Y52.7%
EPS Next 3Y48.26%
EPS Next 5Y30.24%
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PTN. In the last year negative earnings were reported.
Also next year PTN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PTN's earnings are expected to grow with 48.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.7%
EPS Next 3Y48.26%
5. Dividend
5.1 Amount
No dividends for PTN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PALATIN TECHNOLOGIES INC
NYSEARCA:PTN (11/4/2024, 8:04:01 PM)
After market: 1.1605 -0.03 (-2.48%)1.19
-0.01 (-0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap23.26M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -283.18% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.83% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.01 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)18.18%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y0.95%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-7.53%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y